AI
Thursday, June 08, 2017 9:11:09 AM
CASC - 3.82 Pre-market at 3.95/4.00
Cascadian Therapeutics Up 5% Pre-Bell as FDA Grants Orphan Drug Status to Tucatinib For Treating Breast Cancer
Cascadian Therapeutics Up 5% Pre-Bell as FDA Grants Orphan Drug Status to Tucatinib For Treating Breast Cancer
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
